Trial Profile
A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of Intratumoral INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Cisplatin/vinblastine (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms INVINCIBLE-2
- 12 Dec 2023 According to an Intensity Therapeutics media release, company executed agreements with the Ottawa Hospital Research Institute (OHRI) and the Ontario Institute of Cancer Research (OICR) to study INT230-6 in the INVINCIBLE study.
- 09 Dec 2023 Results(n=91)presented at the 46th Annual San Antonio Breast Cancer Symposium
- 08 Dec 2023 According to an Intensity Therapeutics media release, data from this study was presented at a Podium Poster Spotlight discussion session today during the 2023 San Antonio Breast Cancer Symposium (SABCS).